Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Pharmacol Rep ; 2021 Feb 18.
Artigo em Inglês | MEDLINE | ID: mdl-33604795

RESUMO

BACKGROUND: Amantadine is a drug that can help in the prevention of SARS-CoV-2 symptomatology, as has been demonstrated in observational clinical studies. METHODS: We searched in the PubMed database Clinical Studies of coronavirus-infected patients who have been treated with amantadine in a preventive manner as well as patients with Parkinson's disease. RESULTS: Four clinical studies were found in which relatives of patients with COVID-19 had been prescribed the use of amantadine in a preventive manner to avoid the symptoms caused by the coronavirus. CONCLUSION: Amantadine is a drug that can be prescribed as a prophylactic that prevents symptomatology caused by SARS-CoV-2 coronavirus.

2.
MethodsX ; 7: 101135, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33299802

RESUMO

Cell migration is the process by which cells move through tissues, and it is crucial to carry out a wide variety of physiological and pathological processes. The study methods to evaluate cell migration are very useful tools for biomedical research. Among these methods, the wound and healing assay is one of the simplest, most economical and is widely used in research. However, one of its disadvantages is that the width and shape of the wound can vary among experimental samples since the scraping is carried out manually, representing a difficult variable to control. In the present article a variant of the razor scrape assay is addressed, which eliminates this variation in the width of the wound, thus facilitating the measurement and comparison using the total area of cell migration.•A method that can be carried out under standard culture conditions.•Avoids the disadvantage of variation in width and shape of the wound.•It constitutes a simple, cheap option and multiple advantages over the traditional method.

3.
Pharmacol Rep ; 72(6): 1538-1541, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33040252

RESUMO

BACKGROUND: We conducted an observational study of 15 patients from a Southeastern area of Mexico with symptoms compatible with SARS-Cov-2, which were treated with the antiviral amantadine. METHODOLOGY: In this study, data were collected from 15 individuals with clinical symptoms of COVID-19 infection, which were treated on an ambulatory basis with 100 mg of amantadine for a period of 14 days. RESULTS: This drug demonstrated its effectiveness, as patients recovered successfully with this treatment without the necessity of attending a hospital to use mechanical ventilation. All patients developed IgG antibodies to SARS-Cov-2. CONCLUSION: Amantadine can be used as a viable and cost-effective alternative for treating people with severe acute respiratory syndrome (SARS-Cov-2) on an ambulatory basis, while the vaccine is not available.

5.
Arch Med Res ; 51(7): 739-740, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32571606

RESUMO

SARS-Cov-2, whose symptoms include difficulty swallowing, coughing, diarrhea, and breathing failure, has caused the loss of many lives around the world. In the absence of a vaccine or medication to help prevent or decrease the effects of the disease, we suggest that amantadine may reduce the effects of COVID-19.

7.
Clin Interv Aging ; 6: 53-9, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21472092

RESUMO

Alzheimer's disease (AD) is the most common neurodegenerative disorder, originating sporadically in the population aged over 65 years, and advanced age is the principal risk factor leading to AD development. In spite of the large amount of research going on around the globe and all the information now available about AD, there is still no origin or triggering process known so far. Drugs approved for the treatment of AD include tacrine, donepezil, rivastigmine, galantamine, and memantine. These may delay or slow down the degenerative process for a while, but they can neither stop nor reverse its progression. Because that this might be due to a lack of effect of these drugs on degenerating neurons, even when they are able to potentiate the brain in nondegenerative conditions, we propose here an alternative therapy consisting of initial repair of neuronal membranes followed by conventional drug therapies. The rehabilitation of neurons in a degeneration process would enable the drugs to act more effectively on them and improve the effects of treatment in AD patients.


Assuntos
Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/reabilitação , Nootrópicos/uso terapêutico , Fitoterapia , Vitaminas/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Criança , Feminino , Humanos , Degeneração Neural/tratamento farmacológico , Degeneração Neural/reabilitação
8.
Rev. neurol. (Ed. impr.) ; 51(3): 153-164, 1 ago., 2010.
Artigo em Espanhol | IBECS | ID: ibc-86706

RESUMO

Introducción. La enfermedad de Alzheimer (EA) es un trastorno neurodegenerativo de evolución lenta que presenta deterioro cognitivo, pérdida progresiva de la memoria y trastornos en la conducta. El principal factor de riesgo es la edad avanzada. Actualmente, no existe cura para esta enfermedad, por lo que se ha hecho importante el esfuerzo por descubrir métodos de diagnóstico más temprano y de fácil acceso, y tratamientos más efectivos. esarrollo. A escala global se están realizando numerosas investigaciones centradas en la prevención, diagnóstico y tratamiento de la EA. Aquí se revisan los principales aspectos involucrados en el proceso patológico de la enfermedad, con un enfoque en los cambios que generan una respuesta inmune y los posibles marcadores diagnósticos propuestos. Conclusiones. Hoy en día se cuenta con numerosa información sobre la EA; sin embargo, aún es importante continuar la investigación que permita mejorar la calidad de vida de estos pacientes mediante diagnósticos más tempranos y precisos y tratamientos más adecuados (AU)


Introduction. Alzheimer’s disease is a slowly progressing neurodegenerative disease that presents cognitive impairment, progressive loss of memory and conduct disorders. The main risk factor is advanced age. There is currently no cure for this disease and, consequently, important efforts have been made to describe readily accessible methods that allow it to be diagnosed earlier, as well as more effective treatments. Development. A great amount of research focused on the prevention, diagnosis and treatment of Alzheimer’s disease is being carried out around the world. In this study we review the main aspects involved in the pathological process of the disease, with emphasis on the changes that generate an immune response and the possible diagnostic markers that have been proposed. Conclusions. Today, a large body of information on Alzheimer’s disease is available. Nevertheless, it is still important to continue with research that allows these patients to improve their quality of life by means of earlier and more accurate diagnoses, as well as more appropriate treatments (AU)


Assuntos
Humanos , Doença de Alzheimer/imunologia , Biomarcadores/análise , Amiloide/análise , Secretases da Proteína Precursora do Amiloide/análise , Diagnóstico Precoce , Proteínas tau/análise
9.
Rev Neurol ; 51(3): 153-64, 2010 Aug.
Artigo em Espanhol | MEDLINE | ID: mdl-20645266

RESUMO

INTRODUCTION: Alzheimer's disease is a slowly progressing neurodegenerative disease that presents cognitive impairment, progressive loss of memory and conduct disorders. The main risk factor is advanced age. There is currently no cure for this disease and, consequently, important efforts have been made to describe readily accessible methods that allow it to be diagnosed earlier, as well as more effective treatments. DEVELOPMENT: A great amount of research focused on the prevention, diagnosis and treatment of Alzheimer's disease is being carried out around the world. In this study we review the main aspects involved in the pathological process of the disease, with emphasis on the changes that generate an immune response and the possible diagnostic markers that have been proposed. CONCLUSIONS: Today, a large body of information on Alzheimer's disease is available. Nevertheless, it is still important to continue with research that allows these patients to improve their quality of life by means of earlier and more accurate diagnoses, as well as more appropriate treatments.


Assuntos
Doença de Alzheimer/diagnóstico , Doença de Alzheimer/imunologia , Doença de Alzheimer/fisiopatologia , Doença de Alzheimer/terapia , Secretases da Proteína Precursora do Amiloide/metabolismo , Peptídeos beta-Amiloides/metabolismo , Precursor de Proteína beta-Amiloide/metabolismo , Ácido Aspártico Endopeptidases/metabolismo , Biomarcadores/metabolismo , Humanos , Fatores de Risco , Proteínas tau/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...